US to accelerate authorization of COVID-19 vaccines redesigned for omicron

The U.S. is preparing to expedite the authorization of COVID-19 vaccines redesigned to target the omicron variant, The Wall Street Journal reported Dec. 5.

FDA officials met with drugmakers to discuss guidelines for the data the agency will need to quickly assess the revamped vaccines' safety and efficacy, according to the report.